Antidepressant-like properties of sarizotan in experimental Parkinsonism by Zhang, Xiaoqun et al.
ORIGINAL INVESTIGATION
Antidepressant-like properties of sarizotan
in experimental Parkinsonism
Xiaoqun Zhang & Martin Egeland & Per Svenningsson
Received: 15 August 2010 /Accepted: 9 May 2011 /Published online: 7 June 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Rationale Depression and anxiety are common symptoms
in Parkinson's disease for which there are no optimal
treatments. Sarizotan, an agonist at serotonin receptors and
partial agonist at dopamine D2-like receptors, has shown
antidyskinetic effects in Parkinson's disease. Based on its
pharmacological profile, we hypothesized that sarizotan
could also have antidepressant-like properties.
Objectives Examine effects of sarizotan on behavioral and
histological measures known to be regulated by established
antidepressantsinnormalandunilaterally6-hydroxydopamine-
lesioned rats.
Results Sarizotan was found to significantly reduce immo-
bility in the modified forced swim test, a measure of
antidepressant-like activity, but had no effects on thigmo-
taxis or corner time, measures of anxiety-like behavior, in
the unilaterally 6-hydroxydopamine-lesioned rats. At the
same dose, sarizotan counteracted L-DOPA/benserazide-
induced supersentitized rotational behavior and dyskinesias
without significantly affecting L-DOPA/benserazide-in-
duced locomotion. At the histological level, sarizotan alone
or in combination with L-DOPA/benserazide stimulated cell
proliferation, measured by bromodeoxyuridine incorpora-
tion or Ki-67 staining, both in the subgranular zone of the
dentate gyrus and in the subventricular zone of the striatum
in the 6-hydroxydopamine-lesioned hemisphere. Likewise,
combined sarizotan and L-DOPA/benserazide treatment
stimulated doublecortin levels in the subgranular zone of
the dentate gyrus.
Conclusions These significant effects of sarizotan in the
modified forced swim test and on cell proliferation are
reminiscent of those found after various antidepressant
therapies. These data suggest that sarizotan may have
some antidepressant-like and restorative properties in
Parkinsonism.
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Introduction
Sarizotan was developed as a putative atypical antipsychot-
ic agent and exhibits high affinities to serotonin 5-HT1A
receptors and dopamine D4>D3>D2 (i.e., D2-like) receptors
with the profile of a 5-HT1A receptor agonist and D2-like
receptor partial agonist (Bartoszyk et al. 2004). Studies in
animal models of Parkinsonism revealed that sarizotan has
antidyskinetic properties and could represent a new ap-
proach for the treatment of extrapyramidal motor compli-
cations in Parkinson's disease (PD). Indeed, when sarizotan
was systemically administered alone or together with 3,4-
dihydroxy-L-phenylalanine (L-DOPA) to rats rendered
Parkinsonian by unilateral 6-hydroxydopamine (6-
OHDA)-lesioning or to 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-treated nonhuman primates, it attenu-
ated the shortening in motor response duration and
choreiform dyskinesias induced by chronic L-DOPA treat-
ment (Bibbiani et al. 2001). These antidyskinetic effects of
sarizotan occurred without any effects on Parkinsonian
severity or on the antiparkinsonian response to L-DOPA.
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2005; Goetz et al. 2007).
Depression and anxiety are common non-motor symp-
toms in PD (Chaudhuri et al. 2006). Despite the high
incidence of these co-morbidities in PD, there are no
optimized treatments for these conditions. It is known that
5-HT1A receptors are critically involved in the regulation of
mood and emotionality and are thought to mediate some
therapeutic actions of established antidepressants including
selective serotonin reuptake inhibitors (SSRIs) (see, e.g.,
Savitz et al. 2009). Moreover, SSRIs, tricyclic antidepres-
sants, and electroconvulsive shock therapy, all increase
post-synaptic 5-HT1A receptor signaling through direct or
indirect effects (Savitz et al. 2009). Thus, based on its
stimulatory properties of 5-HT1A receptors, sarizotan could
exert antidepressant and anxiolytic actions.
5-HT1A receptor knockout mice display increased
anxiety-related behavior, which cannot be rescued by
antidepressant drug treatment (Ramboz et al. 1998).
Moreover, 5-HT1A receptor knockout mice are insensitive
to the neurogenic effects of fluoxetine, a commonly
prescribed antidepressant and SSRI (Santarelli et al.
2003). Likewise, selective antagonism at 5-HT1A receptors
decreases cell proliferation (Radley and Jacobs 2002) and,
vice versa, stimulation of 5-HT1A receptors increases cell
proliferation (Banasr et al. 2004). Interestingly, the numbers
of proliferating cells in the subventricular zone (SVZ) of
the striatum and in the subgranular zone (SGZ) of the
dentate gyrus are reduced in post-mortem brains of
individuals with PD (Hoglinger et al. 2004). Such reduc-
tions could also be found in experimental Parkinsonism in
rodents and restored by treatment with L-DOPA or selective
agonists at D2-like receptors (Hoglinger et al. 2004; Yang et
al. 2008), with no mention of effects of 5-HT receptor
ligands.
The hypotheses underlying the present study were that
sarizotan, due to its pharmacological profile, may exert
antidepressant- and/or anxiolytic-like behavioral effects and
stimulate cell proliferation in neurogenic brain regions in
experimental Parkinsonism. We therefore used both normal
and unilaterally 6-OHDA-lesioned rats and examined the
behavioral effects of sarizotan in the modified forced swim
test (mFST), a measure of antidepressant-like activity, and
on thigmotaxis or corner time, measures of anxiety-like
behavior. For comparison, behavioral effects of saline,
sarizotan, or L-DOPA/benserazide alone, or in combination,
on rotations, abnormal involuntary movements (AIMs) and
motor activity were measured in the unilaterally 6-OHDA-
lesioned rats. We also examined cell proliferation and
neurogenesis in the neurogenic brain regions, SVZ and
SGZ, in unilaterally 6-OHDA-lesioned rats chronically
treated with saline, sarizotan, or L-DOPA/benserazide alone
or in combination. Bromodeoxyuridine (BrdU), an exoge-
nous compound which incorporates into the DNA of
dividing cells, and Ki-67, an endogenous protein expressed
only during mitosis, were used to measure cell prolifera-
tion. Doublecortin (DCX), a protein present in immature
neurons, was used to measure neurogenesis.
Materials and methods
Animals, surgery, and pharmacological treatment
Male Sprague–Dawley rats (150 g; Scanbur, Sweden) were
used for this study and housed in separate air-conditioned
rooms (12-h dark/light cycle) at 20°C and a humidity of
53%. Experiments were performed in agreement with the
European Communities Council Directive of 24 November
1986 (86/609/EEC) on the ethical use of animals and were
approved by the local ethical committee at Karolinska
Institute.
In most of the experiments, unilaterally 6-OHDA-
lesioned rats were used to mimic aspects of Parkinsonism.
Unilateral 6-OHDA lesioning of nigral dopaminergic axons
was performed as previously described (Zhang et al. 2008).
Briefly, rats were anesthetized with ketamine (80 mg/kg,
i.p.; Parke-Davis, Boxmeer, Netherlands)/xylazine
(10 mg/kg, i.p.; Bayer, Kiel, Germany), pretreated with
desipramine (25 mg/kg, i.p.; Sigma, Stockholm, Sweden)
and pargyline (5 mg/kg, i.p.; Sigma), placed in a stereotaxic
instrument and injected with 6-OHDA (2.5 μlo fa5m g / m l
solution; Sigma) into the medial forebrain bundle of the right
hemisphere (AP −2.8 mm, ML −2.0 mm and V −9.0 mm).
Two weeks after unilateral 6-OHDA lesioning, rats were
administered with apomorphine (1 mg/kg, i.p; Sigma),
and their contralateral rotations were measured over
30 mins. Only rats which rotated contralaterally more
than 100 times were included in further experiments. The
rats were then equally distributed in groups based on
apomorphine-induced rotations for the subsequent experi-
ments. The efficacy of the dopamine denervation was
verified post-mortem by measurements of the striatal
levels of tyrosine hydroxylase (TH) and dopamine
transporter (DAT). Four weeks after the surgery, the
animalswereusedfortheexperiments.6-OHDA-lesionedrats
weretreated withsaline(n=15), and sarizotan (1 mg/kg, n=6
and 2.5 mg/kg, i.p., Merck KGA, n=16) in the acute
experiments studying mFSTand motor activity. We also used
normal rats which were treated with saline (n=6) and
sarizotan (1 mg/kg, n=6 and 2.5 mg/kg, i.p., n=6) in these
acute behavioral experiments. In the chronic experiments
studying rotation, AIMs, motor activity, cell proliferation,
and neurogenesis, 6-OHDA-lesioned rats were treated with
saline (n=4), sarizotan (2.5 mg/kg, i.p., n=5), L-DOPA/
622 Psychopharmacology (2011) 218:621–634benserazide (10/7.5 mg/kg, i.p., Sigma, n=9) alone, or
sarizotan (2.5 mg/kg, i.p.)+L -DOPA/benserazide
(10/7.5 mg/kg, i.p., n= 5 )i nc o m b i n a t i o n .T h r o u g h o u tt h e s e
studies, the methyl ester form of L-DOPA was used. The
choices of dosages of sarizotan and L-DOPA were based on
previous experiments (Bibbiani et al. 2001; Lundblad et al.
2004). At the end of the chronic experiment, the rats were
anesthetized (see above) and perfused (intracardially with
4% paraformaldehyde) 2 h after the last injection.
Behavioral experiments
MFST to measure antidepressant-like activity
We used the mFST (Lucki 1997), which, in comparison to
Porsolt's original test (1977), does not allow the rats to
balance on their tails. It is a 2-day procedure, and we
studied both normal and unilaterally 6-OHDA-lesioned rats.
(The 6-OHDA-lesioned rats were equally distributed in
groups based on apomorphine-induced rotations in 30 min
(saline 137.6±15.7; sarizotan (1 mg/kg) 145.8±12.9;
sarizotan (2.5 mg/kg) 139.2±15.1)). On the first day, the
rats were gently placed individually in a vertical Plexiglas
cylinder (height 45 cm, diameter 19 cm) filled with 26°C
water at a depth (35 cm) that makes it impossible for the rat
to reach the bottom with hind paws. The animals were
removed from the water after 15 min and dried before they
returned to their home cages. The water was changed after
each session. On the second day, the rats were placed in the
same cylinders for 5 min, 30 min postinjection of saline or
sarizotan (1 mg/kg and 2.5 mg/kg, i.p.). The sessions were
video-recorded and an observer, blind to the treatment,
subsequently scored the behavior of the animals. Accord-
i n gt ot h ee s t a b l i s h e dc r i t e r i a( P o r s o l te ta l .1977;L u c k i
1997), the rat was judged to be immobile when it floated
passively, making only small movements to keep its nose
above the surface. Moving limbs to break through the water,
climbing, or diving were scored as activity. After 1 week of
washout,thelocomotionofsameratswasalsotestedfor5min
in open-field boxes 30 min postinjection of saline or sarizotan
(1vs.2.5mg/kg,i.p.).Thepresenteddataarepooledfromtwo
experiments.Inoneexperiment,sixanimalswereusedineach
studied group. In another experiment, only unilaterally 6-
OHDA-lesioned rats treated with saline (n=9) or sarizotan
(2.5 mg/kg; n=10) were examined. The data for the latter
two groups were similar between the two experiments and
therefore it was justified to pool them.
Thigmotaxis and corner time to measure anxiety-like
activity
Thigmotaxis and corner time in an open-field measure the
conflict of an animal to enter open spaces and reflect anxiety-
like responses. Square open-field arenas (680×680×
450 mm) were used to measure thigmotaxis and corner
time (Ericson et al. 1991). The arenas were equipped with
two rows of photocells, sensitive to infrared light, placed
40 and 125 mm above the floor. The photocells were
spaced 90 mm apart, and the last photocell in a row was
spaced 25 mm from the wall. The open field was enclosed
in a ventilated and sound-attenuating box. The variables
recorded were horizontal activity (all interruptions of
photo beams in the lower rows), peripheral activity (all
interruptions of photo beams in the lower rows closest to
the walls), and time spent in the corners of the boxes.
Thigmotaxis is the ratio between peripheral and horizontal
activities. These studies were performed only unilaterally
6-OHDA-lesioned rats and measurements were done for
10 min, 35 min postinjection of saline (n=4), sarizotan (n=5,
2.5 mg/kg, i.p.), L-DOPA/benserazide (n= 9 ,1 0 / 7 . 5m g / k g ,
i.p.) alone, or sarizotan (2.5 mg/kg, i.p.)+L-DOPA/benserazide
(10/7.5 mg/kg, i.p., n=5) in combination acutely or after
24 days of treatment. (The 6-OHDA-lesioned rats were
equally distributed in groups based on apomorphine-
induced rotations in 30 min (saline 210.3±41.0; sarizotan
199.6±38.5; L-DOPA/benserazide 239.9±35.9; sarizotan+
L-DOPA 232.4±42.7).
Measurements of rotations, AIMs, and motor activity
Measurements of rotations, AIMs, and motor activity were
performed sequentially in the same animals acutely and
after 24 days of treatment (and are identical to the animals
used for studies of thigmotaxis and corner time). For
measurements of rotations and AIMs, unilaterally 6-
OHDA-lesioned rats were treated with saline (n=4),
sarizotan (n=5), L-DOPA/benserazide (n=9) alone, or
sarizotan+L-DOPA/benserazide (n=5) in combination and
placed in individual cages. The number of ipsilateral and
contralateral rotations was thereafter counted for 30 min on
days 1 and 24 to measure rapid responses to L-DOPA,
which are known to supersensitize after chronic L-DOPA
administration (Bibbiani et al. 2001). Immediately after the
quantification of rotational behaviors, the incidence of
AIMs was scored for 5 min (Zhang et al. 2008). This
procedure was adapted from a validated rodent scale
(Lundblad et al. 2004). The AIMs were classified into four
subtypes: Forelimb, Orofacial, Axial, and Locomotive
behaviors. Enhanced manifestations of normal behaviors
such as grooming, gnawing, rearing, and sniffing were not
included in the rating. The severity of each AIM subtype
was assessed using scores from 0 to 4 (0: absent, 1:
occasional, i.e., present less than 50% of the time; 2:
frequent, i.e., present more than 50% of the time; 3:
continuous, but interrupted by strong sensory stimuli and 4:
continuous, not interrupted by strong sensory stimuli). Total
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same animals in the open-field arenas (described above) for
10 min, i.e., 35 min postinjection of saline, sarizotan, L-
DOPA/benserazide alone or sarizotan+L-DOPA/bensera-
zide in combination.
BrdU labeling and tissue processing
To assess levels of cell proliferation by the BrdU procedure,
the abovementioned rats which had been treated chronically
with saline, sarizotan, L-DOPA/benserazide, or sarizotan+
L-DOPA/benserazide in combination and studied behavior-
ally in terms of thigmotaxis, corner time, rotations, AIMs,
and motor activity were repeatedly administered with
BrdU. Individual doses of 50 mg/kg BrdU (Sigma) i.p.
were given every 2 h for a total of four injections over 8 h.
Rats were then sacrificed 24 h after the last BrdU injection.
Rats were deeply anesthetized using a combination of
ketamine (80 mg/kg; i.p.) and xylazine (10 mg/kg; i.p.) in
sterile 0.9% saline and were then perfused with phosphate
buffered saline (0.1 M PBS, pH 7.4) followed by perfusion
with 4% paraformaldehyde (Sigma) in 0.1 M PBS. Entire
brains were post-fixed in the same fixative overnight at 4°C
and then cryoprotected by immersion in 30% sucrose in
0.1 M PBS at 4°C for 48 h. Brains were finally frozen and
sectioned at 40 μm using a cryostat at −20°C (Leica
CM1850, Nussloch, Germany) and stored in 0.1 M PBS at
4°C until staining.
Immunohistochemistry
For BrdU and Ki-67 immunohistochemistry, sections were
permeabilized (15 min in 1% Triton X-100/0.1 M PBS),
denaturated (30 mins in 2 M HCl at 37°C), and then
neutralized with boric acid (10 mins at RT in 0.1 M H3BO3
(pH 8.5)). Sections were blocked for 1 h in a blocking
solution (3% Normal Goat Serum, 0.3% Triton X-100 in
0.1 M PBS at RT) followed by incubation overnight in
primary antibody (Rat anti-BrdU, 1:500, Accurate Chem-
ical, Westbury, NY; Rabbit anti-Ki-67, 1:1000, Novocastra,
Newcastle upon Tyne, UK). Sections were then incubated
2 h at RT with an Alexa Fluor immunofluorescent
secondary antibody (anti-rat IgG Alexa Fluor-488, 1:500;
anti-rabbit IgG Alexa Fluor-568 1:200, Molecular Probes,
Invitrogen, Sweden). Sections were finally mounted on
Polylysine coated slides (Histolab, Uppsala, Sweden),
dried, and coverslipped using VECTASHIELD® HardSet™
anti-fade mounting medium (Vector Laboratories, Burlin-
game, CA, USA).
For the DCX and TH immunohistochemistry, staining
were visualized using 3,3′-diaminobenzidine (DAB). Sec-
tions were permeabilized (15 min in 1% Triton X-100/
0.1 M PBS) and blocked against endogenous peroxidases
(20 min with 3% H2O2/0.1 M PBS). Sections were then
incubated with blocking solution for 1 h with serum
followed by the primary antibody (guinea pig anti-DCX,
1:500 or rabbit anti-TH, 1:500, Millipore, Sweden; over-
night at 4°C) and the secondary biotinylated antibody (goat
anti-guinea pig IgG or goat anti-rabbit, 1:200, Vector
Laboratories, Burlingame, CA; 2 h at room temperature).
A signal amplification step was then performed by
incubation in ABC reagent (ABC kit Vector Laboratories,
Burlingame, CA; for 1 h) followed by a reaction with
0.05% DAB-tetrahydrochloride/0.01% hydrogen peroxide
in phosphate buffer. Finally, sections were dehydrated and
mounted on Polylysine coated slides (Histolab), dried, and
coverslipped using VECTASHIELD® HardSet™ anti-fade
mounting medium (Vector Laboratories).
Flourescent or DAB images were captured using a
Nikon Eclipse E600 light microscope connected to a Nikon
digital sight DS-U1 camera using the NIS-Elements F 2.20
software.
BrdU, Ki-67, DCX, and TH quantification procedure
In these experiments, we used an established variation of
design-based sterology to quantify cell proliferation (Malberg
etal. 2000) to investigate sections from the entire structure in
question (SVZ or SGZ). This method differs from true
sterology as it is an estimation of the number of cells in the
entire structure and not an actual sample of cells/volume. In
brief, every eighth section throughout the hippocampus or
SVZ was processed for BrdU, Ki-67, and DCX immunohis-
tochemistry resulting in each section being 320 μma p a r t ,
thus ensuring that the same cell would only be counted once.
The number of BrdU, Ki-67, and DCX labeled cells revealed
by immunofluorescence or DAB staining was then visual-
ized using a fluorescent microscope. Quantification in the
SGZ was done using 40× magnification by an investigator
blind to treatment history who manually counted the
fluorescently labeled BrdU and Ki-67 cells in the granular
cell layer (GCL) and the SGZ, which is defined as a two-cell
soma-wide zone along the base of the GCL. Cells were
considered BrdU, Ki-67, or DCX positive when having
nuclei filled with immunofluorescence or DAB and groups
of clustered cells were counted as one cell. To estimate the
total number of cells in the entire dentate gyrus, the number
of positive cells was therefore multiplied by 8 as only every
eighth section was counted. For quantification in the SVZ,
an investigator blind to treatment history recorded several
images at 20× magnification along the entire SVZ for each
section using image software. The images were then stitched
together using Photoshop (Adobe Photoshop CS), and the
resulting high definition image was then analyzed using
image analysis software (Image J, NIH, Bethesda, USA).
Briefly, the image was converted to an 8-bit black and white
624 Psychopharmacology (2011) 218:621–634image which was then filtered using a preset threshold of
120. Adjoining BrdU staining cells were separated using the
watershed function and finally, BrdU positive cells around or
above the size of a nucleus were quantified using the analyze
particles function. This image analysis method was verified
using a manual counting procedure which gave comparable
values. The numbers of positive cells were again multiplied
by 8 to give an estimation of the total number of cells in the
SVZ.
Sections which had undergone DAB staining of TH were
digitized using a Dia-Scanner (Epson Perfection 4870
PHOTO). Optical density values were measured using
Scion Image for Windows (alfa 4.0.3.2; © 2000–2001
Scion Corporation).
Autoradiographic detection of DAT
Slide mounted sections for detection of DAT were
preincubated in 50 mM Tris–HCl/120 mM NaCl (pH 7.5)
for 20 min. Incubation in binding buffer (50 mM Tris–HCl/
120 mM NaCl, pH 7.5/1 μM fluoxetine) was conducted
with 50 pM [
125I] RTI-55 (Perkin-Elmer Life Sciences,
Boston, USA) for 60 min. For nonspecific binding, 100 μM
nomifensine was added to the assay. The slides were
washed 2×10 s in ice-cold binding buffer, rapidly dipped in
deionized water, dried, and exposed to autoradiographic
films in X-ray cassettes at −20°C for 2–7 days for [
125I]
(BioMax MR, Merck Eurolab, Sweden). The films were
manually developed (Kodak D19, Unifix). Autoradiograms
were digitized using a Dia-Scanner (Epson Perfection 4870
PHOTO), and optical density values were measured using
Scion Image for Windows (alfa 4.0.3.2; © 2000–2001
Scion Corporation).
Statistical analysis
Efficacy of the unilateral 6-OHDA lesioning was analyzed
using student t test. AIMs were analyzed with the non-
parametric Kruskal–Wallis test followed by Dunn's Multi-
ple Comparison Test. All the other behavioral tests and
immunohistochemical data on cell proliferation and neuro-
genesis were analyzed using two-way analysis of variance
(ANOVA) followed by Bonferroni's test for pairwise
comparisons.
Results
Efficacy of the unilateral 6-OHDA lesioning
The efficacy of the unilateral 6-OHDA lesioning in all
studied rats, both from the acute and chronic experiments,
was evaluated by apomorphine-induced rotations (see
above). In addition, in animals from the chronic experi-
ment, post-mortem analysis of the efficacy of the unilateral
6-OHDA lesioning was evaluated by DAB staining of TH
as well as [
125I] RTI-55 binding to DAT. As shown in
Fig. 1, the 6-OHDA lesioning caused a highly significant
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Fig. 1 Effects of unilateral 6-
OHDA lesioning on tyrosine
hydroxylase (TH) and dopamine
transporter (DAT) levels in rats
(n=23). a, b Upper panels show
the DAB staining of TH and
[
125I]RTI-55 autoradiographic
binding of DAT in the striatum
in a unilaterally 6-OHDA-
lesioned rat. c, d Lower panels
show histograms of the quanti-
fication of the efficacy of
6-OHDA lesioning in terms of
reduction of TH and DAT.
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Psychopharmacology (2011) 218:621–634 625and near-complete reduction of TH (t=16.36 and df=42;
p<0.0001) and DAT (t=24.63 and df=22; p<0.0001) at
the level of striatum. There was also a significant
reduction (t=4.85 and df=35; p<0.0001) of DAT binding
at the level of hippocampus (76.96±2.874% of intact
side).
Sarizotan reduced immobility in mFST of unilaterally
6-OHDA-lesioned rats
Learned-helplessness models, in which experimental ani-
mals are exposed to inescapable aversive situations, e.g.,
the mFST, are of utility for predicting antidepressant
efficacy. During these tests, rats show alternate periods of
agitation and immobility (Porsolt et al. 1977; Lucki 1997).
It is well established that acute treatment with various
antidepressant drugs specifically reduces immobility in
these tests without nonspecific increases in motor activity.
Two-way ANOVA analysis (treatment×dopamine level)
showed a significant difference for treatment (F[2,50]:4.0;
p<0.05), but not for the dopamine level (F[1,50]:2.0; p>
0.05) and their interaction (F[2,50]:1.3; p>0.05). Subsequent
pairwise analysis showed that there was a strong trend for
unilaterally 6-OHDA-lesioned rats to be more immobile in
the mFST compared to normal rats (p=0.08). The post-hoc
analysis showed that both doses of sarizotan (1 and
2.5 mg/kg, i.p.) significantly reduced immobility in
unilaterally 6-OHDA-lesioned rats, but not in the normal
rats (Fig. 2a). This reduction in immobility appeared to be
independent of a general increase in motor activity since
sarizotan had no effect on horizontal activity (treatment
(F[2,50]:0.32; p>0.05); dopamine level (F[1,50] 0.68; p>0.05),
or their interaction (F[2,50]:1.9; p>0.05)) neither in unilaterally
6-OHDA-lesioned nor in normal rats (Fig. 2b).
Effects of sarizotan and L-DOPA/benserazide
on thigmotaxis and corner time of unilaterally
6-OHDA-lesioned rats
Thigmotaxis, i.e., peripheral activity divided by total
horizontal activity and corner time are qualitative measures
of motor activity thought to underlie anxiety-like behaviors.
Preliminary data indicated no effect of sarizotan alone on
these measures, so we decided to study effects of sarizotan
alone and in combination with L-DOPA/benserazide. Two-
way ANOVA analysis (treatment×day) showed significant
treatment differences both on thigmotaxis (treatment
(F[3,33]:10.9; p<0.0001); but not on day (F[1,33]:3.34; p>
0.05) or their interaction (F[3,33]:0.82; p>0.05)) and corner
time (treatment (F[3,33]:9.4; p<0.0001); but not on day
(F[1,33]:2.0; p>0.05) or their interaction (F[3,33]:0.03; p>
0.05)). As shown in Fig. 3, pairwise analyses demonstrated
that chronic treatment with L-DOPA/benserazide signifi-
cantly decreased thigmotaxis and corner time compared to
animals treated with saline or sarizotan. Sarizotan alone had
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Fig. 2 Acute treatment with sarizotan reduces immobility in the
modified forced swim test (mFST) of unilaterally 6-OHDA-lesioned but
not inthe normalrats. a The effect of saline and sarizotan on immobility
in the mFST in normal (saline n=6; sarizotan 1 mg/kg n=6; sarizotan
2.5 mg/kg n=6) and unilaterally 6-OHDA-lesioned (saline n=15;
sarizotan 1 mg/kg n=6; sarizotan 2.5 mg/kg n=16) rats. b The effect
of saline and sarizotan on the horizontal activity in the open field of
normal and unilaterally 6-OHDA-lesioned rats. *p<0.05, ***p<0.001
versus saline in the unilaterally 6-OHDA-lesioned rats; two-way
ANOVA followed by Bonferroni's test for pairwise comparisons
626 Psychopharmacology (2011) 218:621–634no effects and no differences between L-DOPA/benserazide-
treated rats and sarizotan+L-DOPA/benserazide-treated rats
on these measures could be found.
Effects of sarizotan on L-DOPA/benserazide-induced
rotations, AIMs, and motor activity in 6-OHDA-lesioned
rats
To confirm that sarizotan, in our experimental setting, has
beneficial actions against the development of motoric L-
DOPA-induced side-effects, we examined whether it could
reduce L-DOPA-induced effects on supersensitized rota-
tions, AIMs, and motor activity. Unilaterally 6-OHDA-
lesioned rats were treated with saline, sarizotan, L-DOPA/
benserazide alone or sarizotan+L-DOPA/benserazide in
combination for 24 days. As shown in Fig. 4a, rotational
behaviors were measured on days 1 and 24, and a two-way
ANOVA analysis (treatment×day) showed a significant
difference for treatment (F[3,38] 14.5; p<0.0001), but not for
the day (F[1,38] 2.85; p>0.05). A significant interaction
between treatment and day was found (F[3,38] 5.59; p<
0.01). Subsequent pairwise analysis showed that sarizotan
alone had no effect on rotations, while for L-DOPA/
benserazide alone, the number of rotations was significantly
increased on day 24. Following co-treatment with sarizotan+
L-DOPA/benserazide for 24 days, there were significantly
fewer rotations compared to treatment with L-DOPA/
benserazide alone. To better characterize the supersensitive
responsivity and possible disadvantageous effects of L-
DOPA/benserazide and its reversal by sarizotan, we also
measured AIMs on day 24. An overall analysis using the
non-parametric Kruskal–Wallis test showed significant dif-
ferences (χ
2 14.23; p<0.001) between the studied groups,
and in agreement with previous studies (e.g., Lundblad et al.
2004; Zhang et al. 2008), repeated L-DOPA/benserazide
treatment increased AIMs when compared to saline (p<0.01)
(Fig. 4b). Moreover, rats co-treated with sarizotan and L-
DOPA/benserazide showed significantly (p<0.05) lower
AIMs scores as compared to rats treated with L-DOPA/
benserazide alone (Fig. 4b). To assess whether the effects of
sarizotan on L-DOPA/benserazide-induced hyperactivity was
related to a general reduction in motor activity or more
specifically involved in lowering AIMs, the motor activity
was measured in open-field boxes on days 1 and 24. A two-
way ANOVA analysis (treatment×day) showed significant
differences on horizontal activity both for treatment (F[3,38]
13.3; p<0.0001) and day (F[1,38] 8.4; p<0.01), but not for
interaction (F[3,38] 0.84; p>0.05). Pairwise analysis showed
that chronic treatment with either L-DOPA/benserazide or
combined sarizotan+L-DOPA/benserazide significantly in-
creased horizontal activity on day 24 when compared to rats
treated with saline or sarizotan alone. No difference between
L-DOPA/benserazide- and sarizotan+L-DOPA/benserazide-
treated rats was found (Fig. 4c). There were no significant
differences between any of the studied groups on rearing
activity (treatment (F[3,38] 0.39; p>0.05);day(F[1,38] 3.6; p>
0.05) or their interaction (F[3,38] 0.26; p>0.05)) (Fig. 4d).
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in a 6-OHDA-lesioned hemisphere
To further examine whether sarizotan may have
antidepressant-like properties, histological measures of cell
proliferation, known to be regulated by antidepressants,
were studied. Unilaterally 6-OHDA-lesioned rats were
subchronically treated with saline, sarizotan, or L-DOPA/
benserazide alone or sarizotan+L-DOPA/benserazide in
combination for 24 days. To examine cell proliferation
using the incorporation of BrdU, rats were treated with
multiple BrdU injections (4×50 mg/kg every 2 h) on the
23rd day and sacrificed 24 h after the last BrdU injection.
Subsequently, immunohistochemical visualization of incor-
porated BrdU staining cells was made in the SVZ (Fig. 5).
Two-way ANOVA analysis (treatment×dopamine level)
showed a significant difference for treatment (F[3,34] 5.7;
p<0.01), but not for the dopamine level (F[1,34] 0.38; p>
0.05) or their interaction (F[3,34] 0.38; p>0.05). Pairwise
analyses showed that treatment with sarizotan or L-DOPA/
benserazide alone or sarizotan+L-DOPA/benserazide in
combination significantly increased cell proliferation in
the 6-OHDA-lesioned side. No significant effect of these
treatments was found in the intact hemisphere.
It was unfortunately impossible to distinguish individual
DCX positive cells in the SVZ as they were densely packed
and no reliable quantification could be performed (data not
shown).
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628 Psychopharmacology (2011) 218:621–634Sarizotan increases cell proliferation and neurogenesis
in the SGZ of the dentate gyrus of hippocampus
in a 6-OHDA-lesioned hemisphere
In the hippocampus, adult neurogenesis occurs in the
granular zone of the dentate gyrus, beginning with cell
proliferation in the SGZ. The experiment was designed to
examine both cell proliferation (measured by BrdU and Ki-
67) and neurogenesis (measured by DCX) in this region. In
studies of BrdU incorporation, a two-way ANOVA analysis
(treatment×dopamine level) showed a significant difference
for treatment (F[3,36] 7.4; p<0.01), but not for the dopamine
level (F[1,36] 1.4; p>0.05) or their interaction (F[3,36] 1.3;
p>0.05). Subsequent pairwise comparisons revealed that
treatment with sarizotan alone or in combination with L-
DOPA/benserazide significantly increased BrdU incorpora-
tion in the 6-OHDA-lesioned side in comparison to saline
as well as L-DOPA/benserazide alone (Fig. 6a, b). No
significant effect of the treatments was found in the intact
hemisphere.
Cell proliferation in the SGZ was also examined using
immunohistochemical visualization of the mitotic marker
Ki-67 (Scholzen and Gerdes 2000). Two-way ANOVA
analysis (treatment×dopamine level) showed a significant
difference on Ki-67 staining for treatment (F[3,38] 5.9; p<
0.01) and for the dopamine level (F[1,38] 12.2; p<0.01), but
not for their interaction (F[3,38 2.4; p>0.05). Pairwise
comparisons of the results from the Ki-67 staining revealed
that sarizotan and L-DOPA/benserazide alone or sarizotan+
L-DOPA/benserazide in combination significantly increased
cell proliferation in the 6-OHDA-lesioned side in the SGZ
in comparison to saline (Fig. 7a, b). There was also a
significant difference between the 6-OHDA-lesioned side
and the intact side in response to treatment with sarizotan
and L-DOPA/benserazide (Fig. 7b). Furthermore, in the
intact side, a significant difference between animals treated
with L-DOPA and sarizotan+L-DOPA/benserazide was
found.
To examine neurogenesis in the SGZ, measurements
of DCX were made. Two-way ANOVA analysis
(treatment×dopamine level) showed a significant differ-
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Psychopharmacology (2011) 218:621–634 629ence for DCX staining for treatment (F[3,36] 2.9; p<
0.05), but not for the dopamine level (F[1,36] 1.6; p>0.05)
or their interaction (F[3,36] 1.2; p>0.05). Pairwise com-
parisons showed that neither sarizotan nor L-DOPA/
benserazide had any significant actions by themselves,
but their combination increased DCX levels in the 6-
OHDA-lesioned side compared to saline and L-DOPA/
benserazide alone (Fig. 8a, b). No significant effect of any
of the studied treatments was found in the intact
hemisphere.
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The major findings of this study are that sarizotan has
antidepressant-like activity in a behavioral and in a
histological measure. In unilaterally 6-OHDA-lesioned rats,
sarizotan significantly reduces immobility in the modified
forced swim test. Moreover, sarizotan stimulates cell
proliferation in both the SGZ and SVZ in the 6-OHDA-
lesioned hemisphere.
One third of the patients suffering from PD exhibit
clinically significant depressive symptoms which contribute
to severe disability, impaired quality of life, and shortened
life expectancy (Chaudhuri et al. 2006; Reijnders et al.
2008). There is a lack of established evidence-based
treatments against depression in PD and a complication is
that resting tremor is worsened by SSRIs in many PD
patients (Chaudhuri et al. 2006). Moreover, it actually
appears that the biochemical responsivity towards SSRIs
differ between PD patients with co-morbid depression and
patients with only depression (Pålhagen et al. 2010). It is
therefore of clinical importance to find novel compounds
for the treatment of depression and anxiety in PD.
In the present study, we hypothesized that sarizotan may
have antidepressant properties. To address this question, we
studied effects of sarizotan in the mFST, an acute test of an
inescapable aversive situation, with predictive validity to
assess antidepressant efficacy (Lucki 1997). Using the
mFST procedure, there was a strong tendency for the
6-OHDA-lesioned rats to be more immobile (“depression-
like”) than normal rats. Interestingly, sarizotan significantly
reduced the immobility of unilaterally 6-OHDA-lesioned
rats. This antidepressant-like effect of sarizotan cannot
simply be explained by a general motor activation since the
same concentration of sarizotan did not have any effect on
horizontal activity in the open field. Sarizotan also tended
to cause an antidepressant-like action in the mFST of
normal rats. To further establish antidepressant properties of
sarizotan, it would be important to study its actions in
additional animal paradigms for antidepressant-like effica-
cy, like the novelty suppressed feeding test (Santarelli et al.
2003). However, bilateral 6-OHDA-lesioned rats or other
symmetric models of Parkinsonism are better suited than
unilaterally 6-OHDA-lesioned rats for analysis in this test.
It is known that 5-HT1A receptors regulate anxiety-like
behaviors and the partial 5-HT1A receptor agonist buspirone
is clinically used as an anxiolytic agent. Based on its
affinity towards 5-HT1A receptors, sarizotan could regulate
anxiety-like behaviors. However, we could not find any
effects of sarizotan on thigmotaxis or corner time in the
open field. These data are in agreement with a previous
study showing that sarizotan had no effect on marble
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for anxiety (Bruins et al. 2008). Future experiments may
evaluate the effects of sarizotan in other tests of anxiety,
such as the elevated plus maze and dark–light box.
Somewhat surprisingly, treatment with L-DOPA/bensera-
zide reduced thigmotaxis and corner time. This effect of L-
DOPA/benserazide cannot be explained by changes in
rearing activity, often reflecting stereotypies, but may be
biased by L-DOPA/benserazide-induced dyskinetic and
rotational behaviors making it more secure for the rat to
stay in the center of the arena. In any case, to our
knowledge, such effects of L-DOPA/benserazide are not
well-characterized and could indicate anxiolytic properties
of L-DOPA/benserazide in hemiparkinsonian rats. It should
also be noted that PCP-treated rats exhibit a reduced
thigmotaxis (Ericson et al. 1991), indicating that certain
psychotomimetic responses may lead to reduced thigmo-
taxis. The functional importance underlying the reduced
thigmotaxis by L-DOPA/benserazide needs to be deter-
mined in follow-up experiments. Sarizotan did not signif-
icantly counteract this action of L-DOPA/benserazide.
Our behavioral data are also in agreement with the
previous studies showing that sarizotan, at 2.5 mg/kg,
exhibited antidyskinetic actions without any effects on
locomotor response to L-DOPA/benserazide in experimental
Parkinsonian rats (Bibbiani et al. 2001; Gerlach et al. 2011).
Bibbiani and co-workers suggested that this effect of
sarizotan could be due to the inhibitory action of 5-HT1A
autoreceptors in regulating the release of dopamine formed
as a false neurotransmitter from exogenous L-DOPA in
serotonin neurons. Indeed, co-treatment with a 5-HT1A
receptor antagonist inhibits the antidyskinetic and sensitiz-
ing effects of sarizotan (Bibbiani et al. 2001; Gerlach et al.
2011). In addition, some specific effects of sarizotan on
locomotive dyskinesia and dystonia are counteracted by D3
receptor agonism (Gerlach et al. 2011). Initial proof-of-
concept trials actually demonstrated an antidyskinetic effect
in patients suffering from PD (Bara-Jimenez et al. 2005),
but this effect could not be replicated in a larger follow-up
trial (Goetz et al. 2007). However, a subpopulation of PD
patients may benefit from sarizotan treatment. Indeed, our
data indicate that advanced PD patients with co-morbid
depression could benefit from sarizotan to prevent the
development of severe dyskinesias and counteract symp-
toms of depression.
To further study antidepressant-like properties of sarizo-
tan, we performed histological studies of its effects on cell
proliferation and neurogenesis. Indeed, it has been shown
that chronic, but not acute, treatment with distinct anti-
depressants increases cell proliferation and neurogenesis in
the SGZ in the dentate gyrus of the hippocampus (Malberg
et al. 2000). As mentioned above, the stimulatory effects of
antidepressants on cell proliferation involves activation of
5-HT1A receptors (Banasr et al. 2004; Radley and Jacobs
2002; Santarelli et al. 2003). Because of the high affinity of
sarizotan at 5-HT1A receptors, the antidepressant-like
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632 Psychopharmacology (2011) 218:621–634actions of sarizotan in the mFST and the lack of knowledge
of serotonergic influence on cell proliferation/neurogenesis
in parkinsonian models, we studied effects of sarizotan on
various aspects of cell proliferation/neurogenesis in unilat-
erally 6-OHDA-lesioned rats. An interesting observation
throughout this histological study was that sarizotan had
more potent effects in the regulation of cell proliferation/
neurogenesis in the 6-OHDA-lesioned hemisphere than in
the intact hemisphere. Measurements of BrdU incorporation
or endogenous Ki-67 staining were used to study cell
proliferation and revealed that treatment with sarizotan
alone or in combination with L-DOPA/benserazide in-
creased cell proliferation in the SGZ of the hippocampus
in the 6-OHDA-lesioned hemisphere. The number of BrdU
positive cells was proportionately smaller to Ki-67. It is
therefore likely that the injected BrdU did not label the
entire population of dividing cells. However, other un-
known factors may also underlie this discrepancy, especial-
ly since L-DOPA/benserazide only increased cell
proliferation when measured with Ki-67. Whereas sarizotan
alone had effects in both assays of cell proliferation in the
SGZ, this was only manifested as a trend for an increase in
neurogenesis, as measured by the immature neuronal
marker DCX. This is not contradictory considering that
DCX is a measure of later stages of the neurogenic process
and not necessarily directly proportionate to cell prolifera-
tion. Neurogenesis was significantly increased in the SGZ
by sarizotan when it was combined with L-DOPA/benser-
azide. Thus, overall, these data support proliferating/
neurogenic effects of sarizotan in the SGZ in a 6-OHDA-
lesioned hemisphere. Based on the literature and the
pharmacological profile of sarizotan, it is likely that 5-
HT1A receptors have a significant role in these histological
actions of sarizotan in the SGZ. However, to definitively
conclude that sarizotan exerts stimulatory effects on cell
proliferation and neurogenesis via stimulation of 5-HT1A
receptors, it would be necessary to perform experiments in
which selective 5-HT1A receptors antagonists and/or 5-
HT1A receptors knockout mice are used to modify the
actions of sarizotan.
It was also found that sarizotan increased cell prolifer-
ation in the SVZ at the level of striatum. In agreement with
previous work (e.g., Hoglinger et al. 2004), L-DOPA/
benserazide also increased cell proliferation in this neuro-
genic niche. No additive effect of sarizotan and L-DOPA
was found. Sarizotan has affinity for dopamine D2-like
receptors which are present in the SVZ and appears to
regulate cell proliferation in this region (Kippin et al. 2005;
Newton and Duman 2007), not least in Parkinsonism
(Hoglinger et al. 2004; Yang et al. 2008). D2-like receptors
could be important in mediating effects of sarizotan on cell
proliferation in the SVZ. Indeed, as pointed out by
Bartoszyk et al. (2004), sarizotan has some intrinsic
dopaminergic activity, as higher doses induce contralateral
rotational behavior in unilaterally 6-OHDA-lesioned rats.
Moreover, recent data (Gerlach et al. 2011) have implicated
D3 receptors in mediating some antidyskinetic and anti-
dystonic responses of sarizotan. It would be informative to
study whether D3 receptor ligands and/or D3 KO mice
modulate effects of sarizotan on cell proliferation, particu-
larly in the SVZ.
In conclusion, the behavioral and neurogenic effects of
sarizotan are reminiscent to the actions of several antide-
pressant agents (Malberg et al. 2000; Sahay and Hen 2007).
These data suggest that compounds with a pharmacological
profile of sarizotan could not only be useful for the
treatment of L-DOPA-induced dyskinesias, but could also
positively influence non-motor symptoms, such as depres-
sion and neurorestorative mechanisms in Parkinsonism.
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